Literature DB >> 2067888

Antibody response to pneumococcal capsular polysaccharide vaccine in African children.

K Temple1, B Greenwood, H Inskip, A Hall, M Koskela, M Leinonen.   

Abstract

Antibody titers to six pneumococcal polysaccharides were measured by enzyme-linked immunosorbent assay in Gambian children before and 1 month after vaccination with a 23-valent pneumococcal capsular polysaccharide vaccine at the ages of 2, 4, 6 or 9 months or at 5 to 10 years of age. IgG responses to type 1, 3 and 5 polysaccharides were seen in children in all age groups. Responses to type 19F and 23F polysaccharides were seen only in the oldest children. Few children of any age responded to immunization with type 6A pneumococcal polysaccharide. The immune response of Gambian infants to immunization with six components of a polyvalent pneumococcal polysaccharide vaccine was comparable with that described previously in Finnish infants and would be unlikely to provide substantial protection against invasive pneumococcal disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2067888     DOI: 10.1097/00006454-199105000-00008

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.

Authors:  Margret Y Richter; Havard Jakobsen; Jean-François Haeuw; Ultan F Power; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

2.  Distribution of capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae isolated from aborigines in central Australia.

Authors:  M Gratten; P Torzillo; F Morey; J Dixon; J Erlich; J Hagger; J Henrichsen
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

3.  Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

Authors:  F M Russell; J R Carapetis; A Balloch; P V Licciardi; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; J Nelson; G B Byrnes; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

Review 4.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea.

Authors:  W S Pomat; D Lehmann; R C Sanders; D J Lewis; J Wilson; S Rogers; T Dyke; M P Alpers
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Recovery of an antiviral antibody response following attrition caused by unrelated infection.

Authors:  Dorothy H L Ng; John J Skehel; George Kassiotis; Jean Langhorne
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

7.  Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses.

Authors:  Stephen B Gordon; Rose Malamba; Neema Mthunthama; Elizabeth R Jarman; Kondwani Jambo; Khuzwayo Jere; Eduard E Zijlstra; Malcolm E Molyneux; John Dennis; Neil French
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.